Multiple myeloma

The Lancet

Volumn 385, Issue 9983, 2015, Pages 2197-2208

  Röllig, Christoph ^a   Knop, Stefan ^b   Bornhäuser, Martin ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; IMMUNOLOGIC FACTOR; PROTEASOME INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CLONAL EVOLUTION; CONFERENCE PAPER; CONSOLIDATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; MAINTENANCE CHEMOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL; SYMPTOM; SYSTEMIC THERAPY; TREATMENT INDICATION; TUMOR MICROENVIRONMENT; BONE MARROW; BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOMODULATION; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMA CELL; PROCEDURES; PROGNOSIS;

BONE MARROW; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS; PROTEASOME INHIBITORS;

EID: 84930091140     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60493-1     Document Type: Conference Paper

References (109)

1. O Landgren, G Gridley, I Turesson et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States Blood 107 2006 904 906
2. National Cancer Institute Surveillance epidemiology and end results program. SEER stat fact sheets on multiple myeloma http://seer.cancer.gov/statfacts/html/mulmy.html 2013 (accessed April 24, 2013).
3. WM Kuehl, PL Bergsagel Molecular pathogenesis of multiple myeloma and its premalignant precursor J Clin Invest 122 2012 3456 3463
4. GT Görgün, G Whitehill, JL Anderson et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans Blood 121 2013 2975 2987
5. W Matsui, Q Wang, JP Barber et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance Cancer Res 68 2008 190 197
6. MA Chapman, MS Lawrence, JJ Keats et al. Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
7. JB Egan, CX Shi, W Tembe et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides Blood 120 2012 1060 1066
8. A Riccardi, PG Gobbi, G Ucci et al. Changing clinical presentation of multiple myeloma Eur J Cancer 27 1991 1401 1405
9. RA Kyle, SV Rajkumar Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 2009 3 9
10. BG Durie, RA Kyle, A Belch the Scientific Advisors of the International Myeloma Foundation Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation Hematol J 4 2003 379 398
11. M Dimopoulos, E Terpos, RL Comenzo the IMWG International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma Leukemia 23 2009 1545 1556
12. A Dispenzieri, MA Gertz, F Buadi What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 26 2012 137 154
13. G Merlini, AD Wechalekar, G Palladini Systemic light chain amyloidosis: an update for treating physicians Blood 121 2013 5124 5130
14. A Dispenzieri, R Kyle, G Merlini the International Myeloma Working Group International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Leukemia 23 2009 215 224
15. BG Durie, JL Harousseau, JS Miguel the International Myeloma Working Group International uniform response criteria for multiple myeloma Leukemia 20 2006 1467 1473
16. N Puig, ME Sarasquete, A Balanzategui et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry Leukemia 28 2014 391 397
17. RA Kyle, ED Remstein, TM Therneau et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma N Engl J Med 356 2007 2582 2590
18. RA Kyle, BG Durie, SV Rajkumar the International Myeloma Working Group Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Leukemia 24 2010 1121 1127
19. Y He, K Wheatley, O Clark et al. Early versus deferred treatment for early stage multiple myeloma Cochrane Database Syst Rev 1 2003 CD004023.
20. N Leung, J Behrens Current approach to diagnosis and management of acute renal failure in myeloma patients Adv Chronic Kidney Dis 19 2012 297 302
21. E Kastritis, E Terpos, MA Dimopoulos Current treatments for renal failure due to multiple myeloma Expert Opin Pharmacother 14 2013 1477 1495
22. AA Chanan-Khan, JF San Miguel, S Jagannath, H Ludwig, MA Dimopoulos Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment Clin Cancer Res 18 2012 2145 2163
23. MA Dimopoulos, J Goldstein, L Fuller, K Delasalle, R Alexanian Curability of solitary bone plasmacytoma J Clin Oncol 10 1992 587 590
24. K Hu, J Yahalom Radiotherapy in the management of plasma cell tumors Oncology (Williston Park) 14 2000 101 108 111.
25. V Reed, J Shah, LJ Medeiros et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy Cancer 117 2011 4468 4474
26. A Palumbo, R Hajek, M Delforge the MM-015 Investigators Continuous lenalidomide treatment for newly diagnosed multiple myeloma N Engl J Med 366 2012 1759 1769
27. M Cavo, P Tacchetti, F Patriarca the GIMEMA Italian Myeloma Network Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 2010 2075 2085
28. L Rosiñol, A Oriol, AI Teruel the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Blood 120 2012 1589 1596
29. GJ Morgan, FE Davies, WM Gregory the National Cancer Research Institute Haematological Oncology Clinical Studies Group Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results Haematologica 97 2012 442 450
30. H Ludwig, R Hajek, E Tóthová et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma Blood 113 2009 3435 3442
31. M Attal, JL Harousseau, AM Stoppa et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome N Engl J Med 335 1996 91 97
32. S Giralt, EA Stadtmauer, JL Harousseau the IMWG International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) Leukemia 23 2009 1904 1912
33. J Koreth, CS Cutler, B Djulbegovic et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials Biol Blood Marrow Transplant 13 2007 183 196
34. A Palumbo, S Bringhen, B Bruno et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study Blood 115 2010 1873 1879
35. A Palumbo, O Sezer, R Kyle the IMWG International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation Leukemia 23 2009 1716 1730
36. M Attal, JL Harousseau, T Facon the InterGroupe Francophone du Myélome Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2003 2495 2502
37. A Kumar, MA Kharfan-Dabaja, A Glasmacher, B Djulbegovic Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis J Natl Cancer Inst 101 2009 100 106
38. B Mohty, J El-Cheikh, I Yakoub-Agha, H Avet-Loiseau, P Moreau, M Mohty Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents Leukemia 26 2012 73 85
39. A Kumar, S Galeb, B Djulbegovic Treatment of patients with multiple myeloma: an overview of systematic reviews Acta Haematol 125 2011 8 22
40. M Boccadoro, F Cavallo, F Gay et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients J Clin Oncol 31 suppl 2013 8509 (abstr).
41. SK Kumar, MQ Lacy, A Dispenzieri et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma Cancer 118 2012 1585 1592
42. JL Harousseau, A Palumbo, PG Richardson et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone Blood 116 2010 3743 3750
43. H Ludwig, H Avet-Loiseau, J Bladé et al. European perspective on multiple myeloma treatment strategies: update following recent congresses Oncologist 17 2012 592 606
44. A Palumbo, K Anderson Multiple myeloma N Engl J Med 364 2011 1046 1060
45. P Kapoor, SV Rajkumar, A Dispenzieri et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis Leukemia 25 2011 689 696
46. JF San Miguel, R Schlag, NK Khuageva et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma J Clin Oncol 31 2013 448 455
47. Y Yeh, J Chambers, S Gaugris et al. Indirect Comparison of the Efficacy of Melphalan-Prednisone-Bortezomib Relative to Melphalan-Prednisone-Thalidomide and Melphalan-Prednisone for the First Line Treatment of Multiple Myeloma ASH Annual Meeting Abstracts 112 2008 2367
48. A Kumar, I Hozo, K Wheatley, B Djulbegovic Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review Am J Hematol 86 2011 18 24
49. JA Zonder, J Crowley, MA Hussein et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) Blood 116 2010 5838 5841
50. SV Rajkumar, S Jacobus, NS Callander the Eastern Cooperative Oncology Group Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 2010 29 37
51. T Facon, M Dimopoulos, A Dispenzieri et al. Initial phase 3 results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT) ASH Annu Meet Abstr 122 2013 2
52. A Palumbo, SV Rajkumar, MA Dimopoulos the International Myeloma Working Group Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2008 414 423
53. A Larocca, F Cavallo, S Bringhen et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Blood 119 2012 933 939
54. A Chanan-Khan, P Sonneveld, MW Schuster et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study J Clin Oncol 26 2008 4784 4790
55. E Vickrey, S Allen, J Mehta, S Singhal Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy Cancer 115 2009 229 232
56. AA Chanan-Khan, S Giralt Importance of achieving a complete response in multiple myeloma, and the impact of novel agents J Clin Oncol 28 2010 2612 2624
57. JL Harousseau, M Attal, H Avet-Loiseau The role of complete response in multiple myeloma Blood 114 2009 3139 3146
58. JJ Lahuerta, MV Mateos, J Martínez-López et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival J Clin Oncol 26 2008 5775 5782
59. HJ van de Velde, X Liu, G Chen, A Cakana, W Deraedt, M Bayssas Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma Haematologica 92 2007 1399 1406
60. M Wang, K Delasalle, L Feng et al. CR represents an early index of potential long survival in multiple myeloma Bone Marrow Transplant 45 2010 498 504
61. P Moreau, M Attal, B Pégourié the IFM 2005-01 study investigators Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial Blood 117 2011 3041 3044
62. HM Lokhorst, B van der Holt, S Zweegman the Dutch-Belgian Hemato-Oncology Group (HOVON) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Blood 115 2010 1113 1120
63. SV Rajkumar, E Blood, D Vesole, R Fonseca, PR Greipp the Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 2006 431 436
64. JL Harousseau, M Attal, H Avet-Loiseau et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 2010 4621 4629
65. AK Stewart, PG Richardson, JF San-Miguel How I treat multiple myeloma in younger patients Blood 114 2009 5436 5443
66. A Palumbo, M Attal, M Roussel Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival Clin Cancer Res 17 2011 1253 1263
67. CB Reeder, DE Reece, V Kukreti et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial Leukemia 23 2009 1337 1341
68. M Kropff, P Liebisch, S Knop the Deutsche Studiengruppe Multiples Myelom DSMM DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma Ann Hematol 88 2009 1125 1130
69. S Kumar, I Flinn, PG Richardson et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Blood 119 2012 4375 4382
70. CB Reeder, DE Reece, V Kukreti et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma Blood 115 2010 3416 3417
71. R Popat, HE Oakervee, S Hallam et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up Br J Haematol 141 2008 512 516
72. P Sonneveld, IG Schmidt-Wolf, B van der Holt et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial J Clin Oncol 30 2012 2946 2955
73. L Garderet, S Iacobelli, P Moreau et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 30 2012 2475 2482
74. PG Richardson, E Weller, S Lonial et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 2010 679 686
75. SV Rajkumar Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management Am J Hematol 87 2012 78 88
76. National Comprehensive Cancer Network NCCN guidelines and derivative information products: user guide http://www.nccn.org/professionals 2013 (accessed April 4, 2013).
77. M Ladetto, G Pagliano, S Ferrero et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma J Clin Oncol 28 2010 2077 2084
78. M Attal, V Lauwers-Cances, G Marit the IFM Investigators Lenalidomide maintenance after stem-cell transplantation for multiple myeloma N Engl J Med 366 2012 1782 1791
79. JR Berenson, JJ Crowley, TM Grogan et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients Blood 99 2002 3163 3168
80. C Shustik, A Belch, S Robinson et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7 Br J Haematol 136 2007 203 211
81. E Fritz, H Ludwig Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients Ann Oncol 11 2000 1427 1436
82. Myeloma Trialists' Collaborative Group Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients Br J Haematol 113 2001 1020 1034
83. AK Nooka, M Behera, LH Boise et al. Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): a meta-analysis ASH Annu Meet Abstr 118 2011 1855
84. C Hahn-Ast, M Lilienfeld-Toal, P Heteren Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma: a meta-analysis of five randomized trials Haematologica 96 suppl 2 2011 884
85. H Ludwig, BG Durie, P McCarthy the International Myeloma Working Group IMWG consensus on maintenance therapy in multiple myeloma Blood 119 2012 3003 3015
86. GJ Morgan, WM Gregory, FE Davies the National Cancer Research Institute Haematological Oncology Clinical Studies Group The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis Blood 119 2012 7 15
87. A Palumbo, S Bringhen, T Caravita the Italian Multiple Myeloma Network GIMEMA Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 2006 825 831
88. P Wijermans, M Schaafsma, F Termorshuizen the Dutch-Belgium Cooperative Group HOVON Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study J Clin Oncol 28 2010 3160 3166
89. A Waage, P Gimsing, P Fayers the Nordic Myeloma Study Group Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma Blood 116 2010 1405 1412
90. M Beksac, R Haznedar, T Firatli-Tuglular et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group Eur J Haematol 86 2011 16 22
91. PL McCarthy, K Owzar, CC Hofmeister et al. Lenalidomide after stem-cell transplantation for multiple myeloma N Engl J Med 366 2012 1770 1781
92. UH Mellqvist, P Gimsing, O Hjertner the Nordic Myeloma Study Group Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial Blood 121 2013 4647 4654
93. J San Miguel, K Weisel, P Moreau et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Lancet Oncol 14 2013 1055 1066
94. DS Siegel, T Martin, M Wang et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825
95. R Vij, DS Siegel, S Jagannath et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib Br J Haematol 158 2012 739 748
96. SV Rajkumar Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management Am J Hematol 86 2011 57 65
97. MA Dimopoulos, MT Petrucci, R Foa et al. Analysis of second-Line lenalidomide following initial relapse in the MM-015 trial ASH Annu Meet Abstr 120 2012 944
98. CL Alvares, FE Davies, C Horton, G Patel, R Powles, GJ Morgan The role of second autografts in the management of myeloma at first relapse Haematologica 91 2006 141 142
99. K Neben, L Sellner, C Heiss et al. Autologous Re-transplantation for patients with relapsed multiple myeloma: a single center experience with 200 patients ASH Annu Meet Abstr 120 2012 3086
100. JP Fermand, P Ravaud, S Chevret et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood 92 1998 3131 3136
101. DH Vesole, JJ Crowley, R Catchatourian et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial J Clin Oncol 17 1999 2173 2179
102. S Kumar, MJ Zhang, P Li et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis Blood 118 2011 1979 1988
103. R Mhaskar, J Redzepovic, K Wheatley et al. Bisphosphonates in multiple myeloma: a network meta-analysis Cochrane Database Syst Rev 5 2012 CD003188.
104. E Terpos, G Morgan, MA Dimopoulos et al. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease J Clin Oncol 31 2013 2347 2357
105. MQ Lacy, A Dispenzieri, MA Gertz et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma Mayo Clin Proc 81 2006 1047 1053
106. M Dickinson, HM Prince, S Kirsa et al. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment Intern Med J 39 2009 304 316
107. SY Kristinsson, O Landgren, PW Dickman, AR Derolf, M Björkholm Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003 J Clin Oncol 25 2007 1993 1999
108. SK Kumar, SV Rajkumar, A Dispenzieri et al. Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2008 2516 2520
109. SK Kumar, A Dispenzieri, MA Gertz et al. Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents ASH Annu Meet Abstr 120 2012 3972